These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
115 related articles for article (PubMed ID: 15370797)
1. Can brain natriuretic peptide (BNP) be used as a screening tool in general practice? Schaufelberger M; Bergh CH; Caidahl K; Eggertsen R; Furenäs E; Lindstedt G; Nilsson T; Stefferud K; Swedberg K Scand J Prim Health Care; 2004 Sep; 22(3):187-90. PubMed ID: 15370797 [TBL] [Abstract][Full Text] [Related]
2. Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. Ng LL; Pathik B; Loke IW; Squire IB; Davies JE Am Heart J; 2006 Jul; 152(1):94-101. PubMed ID: 16824837 [TBL] [Abstract][Full Text] [Related]
3. Right heart overload contributes to cardiac natriuretic hormone elevation in patients with heart failure. Passino C; Maria Sironi A; Favilli B; Poletti R; Prontera C; Ripoli A; Lombardi M; Emdin M Int J Cardiol; 2005 Sep; 104(1):39-45. PubMed ID: 16137508 [TBL] [Abstract][Full Text] [Related]
4. N-terminal prohormone brain natriuretic peptide as a marker for detecting low functional class patients and candidates for cardiac transplantation: linear correlation with exercise tolerance. Kallistratos MS; Dritsas A; Laoutaris ID; Cokkinos DV J Heart Lung Transplant; 2007 May; 26(5):516-21. PubMed ID: 17449423 [TBL] [Abstract][Full Text] [Related]
5. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. Jourdain P; Jondeau G; Funck F; Gueffet P; Le Helloco A; Donal E; Aupetit JF; Aumont MC; Galinier M; Eicher JC; Cohen-Solal A; Juillière Y J Am Coll Cardiol; 2007 Apr; 49(16):1733-9. PubMed ID: 17448376 [TBL] [Abstract][Full Text] [Related]
6. Plasma brain natriuretic peptide predicts short-term clinical outcome in heart failure patients with restrictive filling pattern. Feola M; Aspromonte N; Milani L; Bobbio M; Bardellotto S; Barro S; Giovinazzo P; Noventa F; Valle R J Card Fail; 2008 Jun; 14(5):420-5. PubMed ID: 18514935 [TBL] [Abstract][Full Text] [Related]
7. [Screening for asymptomatic left ventricular systolic dysfunction in high-risk patients. Preliminary experience with a program based on the use of ECG and natriuretic peptide]. Tarantini L; Cioffi G; Di Lenarda A; Valle R; Pulignano G; Del Sindaco D; Frigo G; Soravia G; Tessier R; Catania G G Ital Cardiol (Rome); 2008 Dec; 9(12):835-43. PubMed ID: 19119693 [TBL] [Abstract][Full Text] [Related]
8. Interleukin-6 and tumor necrosis factor-alpha as biochemical markers of heart failure: a head-to-head clinical comparison with B-type natriuretic peptide. Boffa GM; Zaninotto M; Sartor R; Mion M; Berton A; Pasqualetto C; Razzolini R; Plebani M J Cardiovasc Med (Hagerstown); 2009 Oct; 10(10):758-64. PubMed ID: 19553828 [TBL] [Abstract][Full Text] [Related]
9. Correlations between clinical presentation, brain natriuretic peptide, big endothelin-1, tumor necrosis factor-alpha and cardiac troponins in heart failure patients. Boffa GM; Zaninotto M; Bacchiega E; Nalli C; Forni M; Tiso E; Cacciavillani L; Razzolini R; Plebani M Ital Heart J; 2005 Feb; 6(2):125-32. PubMed ID: 15819505 [TBL] [Abstract][Full Text] [Related]
13. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. Richards M; Nicholls MG; Espiner EA; Lainchbury JG; Troughton RW; Elliott J; Frampton CM; Crozier IG; Yandle TG; Doughty R; MacMahon S; Sharpe N; ; J Am Coll Cardiol; 2006 Jan; 47(1):52-60. PubMed ID: 16386664 [TBL] [Abstract][Full Text] [Related]
14. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998 [TBL] [Abstract][Full Text] [Related]
15. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. Nishii M; Inomata T; Takehana H; Naruke T; Yanagisawa T; Moriguchi M; Takeda S; Izumi T J Am Coll Cardiol; 2008 Jun; 51(24):2329-35. PubMed ID: 18549918 [TBL] [Abstract][Full Text] [Related]
16. Prognostic usefulness of anemia and N-terminal pro-brain natriuretic peptide in outpatients with systolic heart failure. Schou M; Gustafsson F; Kistorp CN; Corell P; Kjaer A; Hildebrandt PR Am J Cardiol; 2007 Nov; 100(10):1571-6. PubMed ID: 17996522 [TBL] [Abstract][Full Text] [Related]
17. Brain natriuretic peptide is a good predictor for outcome in cardiac surgery. Elíasdóttir SB; Klemenzson G; Torfason B; Valsson F Acta Anaesthesiol Scand; 2008 Feb; 52(2):182-7. PubMed ID: 17949462 [TBL] [Abstract][Full Text] [Related]
18. Correlation of B type natriuretic peptides with clinical and echocardiographic parameters in heterogeneous population of patients with symptoms suggestive of heart failure. Piechota WN; Piechota WT; Bejm J; Wierzbowski R; Michałkiewicz D Adv Med Sci; 2006; 51():164-7. PubMed ID: 17357300 [TBL] [Abstract][Full Text] [Related]
19. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Berger R; Huelsmann M; Strecker K; Moertl D; Moser P; Bojic A; Pacher R Eur J Clin Invest; 2005 Jan; 35(1):24-31. PubMed ID: 15638816 [TBL] [Abstract][Full Text] [Related]
20. N-terminal pro-B-type natriuretic peptide is an independent predictor of outcome in an unselected cohort of critically ill patients. Meyer B; Huelsmann M; Wexberg P; Delle Karth G; Berger R; Moertl D; Szekeres T; Pacher R; Heinz G Crit Care Med; 2007 Oct; 35(10):2268-73. PubMed ID: 17717488 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]